Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 349 | 64 | 282 |
| Samples | 183 | 43 | 138 |
| Peptides | 138 | 30 | 110 |
Function
ELANE · Elastase, neutrophil expressed
Elastases form a subfamily of serine proteases that hydrolyze many proteins in addition to elastin. Humans have six elastase genes which encode structurally similar proteins. The encoded preproprotein is proteolytically processed to generate the active protease. Following activation, this protease hydrolyzes proteins within specialized neutrophil lysosomes, called azurophil granules, as well as proteins of the extracellular matrix. The enzyme may play a role in degenerative and inflammatory diseases through proteolysis of collagen-IV and elastin. This protein also degrades the outer membrane protein A (OmpA) of E. coli as well as the virulence factors of such bacteria as Shigella, Salmonella and Yersinia. Mutations in this gene are associated with cyclic neutropenia and severe congenital neutropenia (SCN). This gene is present in a gene cluster on chromosome 19. [provided by RefSeq, Jan 2016].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 137 amino-acid changes on canonical ENST00000263621 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ELANE · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ELANE – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Melanoma | 4/210 2% | 17/1899 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Endometrial Carcinoma | 4/42 10% | 2/612 0% |
| Colorectal Carcinoma | 1/143 1% | 27/3239 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 11/1592 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 3/810 0% |
| Gastric Carcinoma | 0/74 0% | 13/1809 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Other Solid Cancers | 2/94 2% | 5/1515 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Hepatocellular Carcinoma | 1/46 2% | 9/2210 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Ovarian Carcinoma | 3/109 3% | 1/998 0% |
| Non-Cancerous | 1/104 1% | 2/830 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 5/1390 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 2/2534 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Other Blood Cancers | 0/61 0% | 4/2725 0% |
Mutation Distribution
Where ELANE is mutated · all tissues, split by cell line vs tissue
How many mutations in ELANE were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 349 mutations in ELANE
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|